Kyverna Therapeutics Inc (KYTX)

$8.61 -0.23 (-2.60%)
Market Cap 546.69M
Revenue (ttm) 0.00
Net Income (ttm) -161.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 413,800
Avg Vol 1,068,658
Day's Range N/A - N/A
Shares Out 61.84M
Stochastic %K 60%
Beta 1.93
Analysts Strong Sell
Price Target $30.40

Company Profile

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product cand...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 925 2492
Address:
5980 Horton Street, Suite 550, EmeryVille, United States
ZackInvest008
ZackInvest008 Aug. 25 at 7:23 PM
$KYTX Whoa
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Aug. 25 at 6:06 PM
$KYTX is undoubtedly one of the sleeping giants in the biotech/pharma sector atm. These guys are building a platform, not just one treatment. 5 Billion valuation in 2027 possible once retail FOMO kicks in. 10x from here 💲📈💲
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Aug. 25 at 6:00 PM
$KYTX https://www.cgtlive.com/view/miv-cel-rmat-designation-progressive-multiple-sclerosis
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Aug. 25 at 5:56 PM
$KYTX https://www.thepharmaletter.com/ones-to-watch/kyverna-therapeutics
0 · Reply
ValueBioTracker
ValueBioTracker Aug. 25 at 3:52 PM
$KYTX Q3 data readout for SPS and gMG should take it to $13 per share. I'm patient
1 · Reply
vu_jade
vu_jade Aug. 25 at 2:02 PM
$KYTX Breakout watch
0 · Reply
InsaneZane
InsaneZane Aug. 25 at 11:00 AM
$KYTX why is this such a pain in my ass?
0 · Reply
Strat
Strat Aug. 21 at 5:22 PM
$KYTX From the Clinical.Gov site, they show the last comments on the 12 month KYSA-8 trial were entered on 7/24/26 and the 12 month SPS data has all been gathered. The active treatment window is closed and has crossed the finish line. What's Next? - Data Cleaning and Locking ->no missing data - Statistical Analysis -> the math has to be done for 12 month full metrics. - Presentation/Package -> Clean "Top Line" PR and package final clinical modules for FDA. This all means data could drop any day once everything is done per SEC compliance with disclosure. Look out shorts you could get burned here as the data has been very positive so far. If you are thinking about entering this stock do your DD. I wanted to share my thoughts here just to add some color. GLT longs!
1 · Reply
vu_jade
vu_jade Aug. 21 at 4:04 PM
$KYTX long
0 · Reply
ZackInvest008
ZackInvest008 Aug. 20 at 10:44 PM
$KYTX
1 · Reply
Latest News on KYTX
Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)

2026-08-11T20:15:41.000Z - 15 days ago

Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Aug 11, 2026, 4:02 PM EDT - 15 days ago

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Kyverna Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 15 days ago

Kyverna Therapeutics Earnings release: Q2 2026

Kyverna Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 15 days ago

Kyverna Therapeutics Quarterly report: Q2 2026

Kyverna Therapeutics Slides: Corporate presentation

Aug 11, 2026, 7:00 AM EDT - 15 days ago

Kyverna Therapeutics Slides: Corporate presentation

Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement

2026-07-27T12:11:33.000Z - 4 weeks ago

Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

Jul 27, 2026, 8:00 AM EDT - 4 weeks ago

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer

2026-06-22T12:11:14.000Z - 2 months ago

Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:10 PM EDT - 3 months ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Kyverna Therapeutics presents updated COMPARE trial data at EULAR

2026-06-03T13:00:42.000Z - 3 months ago

Kyverna Therapeutics presents updated COMPARE trial data at EULAR

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Jun 3, 2026, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics Slides: Corporate presentation

Jun 3, 2026, 7:00 AM EDT - 3 months ago

Kyverna Therapeutics Slides: Corporate presentation

Kyverna Therapeutics Transcript: AGM 2026

May 27, 2026, 2:00 PM EDT - 3 months ago

Kyverna Therapeutics Transcript: AGM 2026

Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 2:30 PM EDT - 3 months ago

Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed

2026-05-18T12:16:11.000Z - 3 months ago

Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed

IRWD

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

May 18, 2026, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

2026-05-15T10:20:21.000Z - 3 months ago

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

Kyverna Therapeutics to Present at Upcoming Investor Conferences

May 14, 2026, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

2026-05-13T11:20:39.000Z - 3 months ago

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

2026-05-12T22:38:44.000Z - 3 months ago

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

May 12, 2026, 4:02 PM EDT - 3 months ago

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

Kyverna Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

Kyverna Therapeutics Earnings release: Q1 2026

Kyverna Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

Kyverna Therapeutics Quarterly report: Q1 2026

Kyverna Therapeutics Slides: Investor presentation

May 12, 2026, 7:00 AM EDT - 3 months ago

Kyverna Therapeutics Slides: Investor presentation

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

2026-05-04T12:45:05.000Z - 4 months ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

OMER

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

May 4, 2026, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Kyverna Therapeutics Transcript: Status update

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Transcript: Status update

Kyverna Therapeutics Press release: Status update

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Press release: Status update

Kyverna Therapeutics Slides: Status update

Apr 22, 2026, 7:00 AM EDT - 4 months ago

Kyverna Therapeutics Slides: Status update

Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel

2026-04-21T22:50:16.000Z - 4 months ago

Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Apr 21, 2026, 6:45 PM EDT - 4 months ago

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel

2026-04-20T13:12:24.000Z - 4 months ago

Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Kyverna Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Proxy statement: Proxy filing

Kyverna Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Proxy statement: Proxy filing

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

Kyverna Therapeutics files $300M mixed securities shelf

2026-03-26T20:25:22.000Z - 5 months ago

Kyverna Therapeutics files $300M mixed securities shelf

Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)

2026-03-26T20:12:42.000Z - 5 months ago

Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 26, 2026, 4:02 PM EDT - 5 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Kyverna Therapeutics Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Kyverna Therapeutics Annual report: Q4 2025

Kyverna Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Kyverna Therapeutics Earnings release: Q4 2025

Kyverna Therapeutics Registration statement: Registration filing

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Kyverna Therapeutics Registration statement: Registration filing

Kyverna Therapeutics Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Kyverna Therapeutics Slides: Corporate presentation

Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 11:20 AM EDT - 6 months ago

Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Mar 5, 2026, 4:21 PM EST - 6 months ago

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

Mar 3, 2026, 8:00 AM EST - 6 months ago

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board

2026-02-24T13:20:34.000Z - 6 months ago

Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board

BEAM

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Feb 24, 2026, 8:00 AM EST - 6 months ago

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

Kyverna Therapeutics appoints Pujols as Chief Technology Officer

2026-02-03T13:25:38.000Z - 7 months ago

Kyverna Therapeutics appoints Pujols as Chief Technology Officer

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Feb 3, 2026, 8:00 AM EST - 7 months ago

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 8 months ago

Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 8 months ago

Kyverna Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics provides corporate update, priorities for 2026

2026-01-12T13:38:56.000Z - 8 months ago

Kyverna Therapeutics provides corporate update, priorities for 2026

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 8 months ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Kyverna Therapeutics Slides: Investor presentation

Jan 12, 2026, 7:00 AM EST - 8 months ago

Kyverna Therapeutics Slides: Investor presentation

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 8 months ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Dec 17, 2025, 9:24 AM EST - 9 months ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 9 months ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Kyverna Therapeutics Transcript: Study Result

Dec 15, 2025, 8:00 AM EST - 9 months ago

Kyverna Therapeutics Transcript: Study Result

Kyverna Therapeutics Press release: Study Result

Dec 15, 2025, 8:00 AM EST - 9 months ago

Kyverna Therapeutics Press release: Study Result

Kyverna Therapeutics Slides: Study Result

Dec 15, 2025, 8:00 AM EST - 9 months ago

Kyverna Therapeutics Slides: Study Result

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:42 AM EST - 9 months ago

Kyverna's cell therapy meets main goal of mid-stage study

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 15, 2025, 6:30 AM EST - 9 months ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 9 months ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 8:00 AM EST - 10 months ago

Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:05 PM EST - 10 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Kyverna Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Kyverna Therapeutics Earnings release: Q3 2025

Kyverna Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Kyverna Therapeutics Quarterly report: Q3 2025

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 10, 2025, 8:00 AM EST - 10 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Nov 3, 2025, 8:00 AM EST - 10 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Kyverna Therapeutics Transcript: Study Update

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Kyverna Therapeutics Transcript: Study Update

Kyverna Therapeutics Press release: Study Update

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Kyverna Therapeutics Press release: Study Update

Kyverna Therapeutics Slides: Study Update

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Kyverna Therapeutics Slides: Study Update

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 29, 2025, 6:30 AM EDT - 10 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 25, 2025, 11:00 AM EDT - 10 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Oct 22, 2025, 8:00 AM EDT - 11 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 24, 2025, 9:05 AM EDT - 1 year ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Sep 15, 2025, 1:02 PM EDT - 1 year ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Kyverna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:05 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Kyverna Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Kyverna Therapeutics Transcript: KOL Event

Aug 28, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Transcript: KOL Event

Kyverna Therapeutics Press release: KOL Event

Aug 28, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Press release: KOL Event

Kyverna Therapeutics Slides: KOL Event

Aug 28, 2025, 11:00 AM EDT - 1 year ago

Kyverna Therapeutics Slides: KOL Event

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 25, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Kyverna Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Quarterly report: Q2 2025

Kyverna Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q2 2025

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 4:55 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Quarterly report: Q1 2025

Kyverna Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q1 2025

Kyverna Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Proxy statement: Proxy Filing

Kyverna Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Proxy statement: Proxy Filing

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:02 PM EDT - 1 year ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Annual report: Q4 2024

Kyverna Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Kyverna Therapeutics Earnings release: Q4 2024

Kyverna Therapeutics Registration statement: Registration Filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Kyverna Therapeutics Registration statement: Registration Filing

Kyverna Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Kyverna Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

ZackInvest008
ZackInvest008 Aug. 25 at 7:23 PM
$KYTX Whoa
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Aug. 25 at 6:06 PM
$KYTX is undoubtedly one of the sleeping giants in the biotech/pharma sector atm. These guys are building a platform, not just one treatment. 5 Billion valuation in 2027 possible once retail FOMO kicks in. 10x from here 💲📈💲
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Aug. 25 at 6:00 PM
$KYTX https://www.cgtlive.com/view/miv-cel-rmat-designation-progressive-multiple-sclerosis
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker Aug. 25 at 5:56 PM
$KYTX https://www.thepharmaletter.com/ones-to-watch/kyverna-therapeutics
0 · Reply
ValueBioTracker
ValueBioTracker Aug. 25 at 3:52 PM
$KYTX Q3 data readout for SPS and gMG should take it to $13 per share. I'm patient
1 · Reply
vu_jade
vu_jade Aug. 25 at 2:02 PM
$KYTX Breakout watch
0 · Reply
InsaneZane
InsaneZane Aug. 25 at 11:00 AM
$KYTX why is this such a pain in my ass?
0 · Reply
Strat
Strat Aug. 21 at 5:22 PM
$KYTX From the Clinical.Gov site, they show the last comments on the 12 month KYSA-8 trial were entered on 7/24/26 and the 12 month SPS data has all been gathered. The active treatment window is closed and has crossed the finish line. What's Next? - Data Cleaning and Locking ->no missing data - Statistical Analysis -> the math has to be done for 12 month full metrics. - Presentation/Package -> Clean "Top Line" PR and package final clinical modules for FDA. This all means data could drop any day once everything is done per SEC compliance with disclosure. Look out shorts you could get burned here as the data has been very positive so far. If you are thinking about entering this stock do your DD. I wanted to share my thoughts here just to add some color. GLT longs!
1 · Reply
vu_jade
vu_jade Aug. 21 at 4:04 PM
$KYTX long
0 · Reply
ZackInvest008
ZackInvest008 Aug. 20 at 10:44 PM
$KYTX
1 · Reply
blocktrade
blocktrade Aug. 20 at 5:47 PM
$KYTX looking forward to the day these nickel and dime traders get fking run over once and for all
2 · Reply
rjalagam9111
rjalagam9111 Aug. 20 at 4:35 PM
$KYTX why this is going down so quick ?
0 · Reply
blocktrade
blocktrade Aug. 19 at 6:29 PM
$KYTX can’t hold a fart
3 · Reply
hummer2277
hummer2277 Aug. 19 at 3:02 PM
$KYTX labu on
0 · Reply
tmoney4572
tmoney4572 Aug. 19 at 2:32 PM
$KYTX
0 · Reply
hbkstockislife
hbkstockislife Aug. 19 at 2:06 PM
$KYTX running
0 · Reply
tmoney4572
tmoney4572 Aug. 19 at 10:31 AM
$KYTX then you will never buy
0 · Reply
Greenenergy33
Greenenergy33 Aug. 19 at 9:03 AM
$KYTX I will buy at 5.
2 · Reply
dcrown
dcrown Aug. 18 at 2:24 PM
$KYTX stop the selling
1 · Reply
ak123456790
ak123456790 Aug. 18 at 5:55 AM
$KYTX This company is a hidden gem ! Now the big funds still accumulate shares with the help of MMs , that is why you see those ups and downs but always controlled …The float is small so it takes months for big boys to get the number of shares they want ! When they are done, then the price will climb ! Still cheap!
1 · Reply
Belisimo
Belisimo Aug. 17 at 8:25 PM
$KYTX Looking good
1 · Reply
kenny91655
kenny91655 Aug. 17 at 7:29 PM
$KYTX Out, wait for a pullback to 7's if market allows.
3 · Reply